PDC Therapeutics on Innovaud Annual Report 2020

For the Innovaud Report Page

For The Innovaud News Page

 

“PDC THERAPEUTICS PAVES THE WAY FOR MORE EFFECTIVE AND LESS TOXIC CHEMOTHERAPY

The company PDC Therapeutics, recently installed within the Biopôle campus, is a company in the therapeutic field which exploits a new drug delivery technology making it possible to deliver anticancer treatments directly to a tumor. The toxicity to the rest of the body is thus reduced. The start-up uses proprietary platforms initially developed by RS Research, an Istanbul-based research company, to present its offering. PDC Therapeutics co-founder Sena Nomak, also co-founder of RS Research, explains how his Polymer-Drug Conjugates (abbreviated PDC) are opening up promising new perspectives in the field of oncology – and why he chose the canton of Vaud for the headquarters of his biotechnology company in clinical phase.”

“Since its merger in 2020 with DEV (Economic Development – Canton of Vaud), Innovaud has also been tasked with assisting foreign firms wishing to establish themselves in the canton. The interest of international investors did not dry up last year: despite travel restrictions, 20 foreign companies were set up (compared to 32 in 2019), with the support of Innovaud and the organizations in charge of prospecting in foreign markets. These companies, active in fields such as ICT, cleantech and life sciences, came mainly from France, the United Kingdom, Belgium and Turkey. 213 jobs are announced at 5 years in the canton. The profiles of two companies established last year, Delio and PDC Therapeutics, are published in the annual report of Innovaud.”